Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Liabilities and Shareholders Equity: 2020-2025

Historic Liabilities and Shareholders Equity for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $195.0 million.

  • Caribou Biosciences' Liabilities and Shareholders Equity fell 43.37% to $195.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year decrease of 35.56%. This contributed to the annual value of $313.3 million for FY2024, which is 27.51% down from last year.
  • Latest data reveals that Caribou Biosciences reported Liabilities and Shareholders Equity of $195.0 million as of Q3 2025, which was down 11.73% from $220.9 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Liabilities and Shareholders Equity ranged from a high of $462.0 million in Q3 2021 and a low of $158.4 million during Q2 2021.
  • For the 3-year period, Caribou Biosciences' Liabilities and Shareholders Equity averaged around $337.6 million, with its median value being $347.5 million (2023).
  • As far as peak fluctuations go, Caribou Biosciences' Liabilities and Shareholders Equity soared by 1,127.20% in 2021, and later slumped by 43.37% in 2025.
  • Over the past 5 years, Caribou Biosciences' Liabilities and Shareholders Equity (Quarterly) stood at $442.4 million in 2021, then declined by 15.51% to $373.8 million in 2022, then increased by 15.64% to $432.2 million in 2023, then decreased by 27.51% to $313.3 million in 2024, then tumbled by 43.37% to $195.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $195.0 million in Q3 2025, compared to $220.9 million in Q2 2025 and $273.7 million in Q1 2025.